Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

288 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study.
von Minckwitz G, Kümmel S, du Bois A, Eiermann W, Eidtmann H, Gerber B, Hilfrich J, Huober J, Costa SD, Jackisch C, Grasshoff ST, Vescia S, Skacel T, Loibl S, Mehta KM, Kaufmann M; German Breast Group. von Minckwitz G, et al. Among authors: huober j. Ann Oncol. 2008 Feb;19(2):292-8. doi: 10.1093/annonc/mdm438. Epub 2007 Sep 9. Ann Oncol. 2008. PMID: 17846019 Free article. Clinical Trial.
[Adjuvant endocrine therapy in breast cancer].
Huober J, Thürlimann B. Huober J, et al. Ther Umsch. 2008 Apr;65(4):193-200. doi: 10.1024/0040-5930.65.4.193. Ther Umsch. 2008. PMID: 18622910 Review. German.
[New treatment approaches in breast cancer].
Spirig C, Thürlimann B, Huober J. Spirig C, et al. Among authors: huober j. Ther Umsch. 2008 Apr;65(4):207-10. doi: 10.1024/0040-5930.65.4.207. Ther Umsch. 2008. PMID: 18622912 German.
Adjuvant! When the new world meets the old world.
Huober J, Thürlimann B. Huober J, et al. Lancet Oncol. 2009 Nov;10(11):1028-9. doi: 10.1016/S1470-2045(09)70323-7. Lancet Oncol. 2009. PMID: 19880058 No abstract available.
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
von Minckwitz G, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kühn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Untch M. von Minckwitz G, et al. Among authors: huober j. J Clin Oncol. 2010 Apr 20;28(12):2015-23. doi: 10.1200/JCO.2009.23.8303. Epub 2010 Mar 22. J Clin Oncol. 2010. PMID: 20308671 Clinical Trial.
Bone targeted therapy in breast cancer: present and future.
Huober J, Thürlimann B. Huober J, et al. Crit Rev Oncol Hematol. 2010 Apr;74 Suppl 1:S7-10. doi: 10.1016/S1040-8428(10)70004-4. Crit Rev Oncol Hematol. 2010. PMID: 20427030 Review. No abstract available.
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06).
Rochlitz C, Ruhstaller T, Lerch S, Spirig C, Huober J, Suter T, Bühlmann M, Fehr M, Schönenberger A, von Moos R, Winterhalder R, Rauch D, Müller A, Mannhart-Harms M, Herrmann R, Cliffe B, Mayer M, Zaman K; Swiss Group for Clinical Cancer Research (SAKK). Rochlitz C, et al. Among authors: huober j. Ann Oncol. 2011 Jan;22(1):80-85. doi: 10.1093/annonc/mdq319. Epub 2010 Jul 1. Ann Oncol. 2011. PMID: 20595448 Free article. Clinical Trial.
288 results